Navigation Links
Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds

SAINT PAUL, Minn., Oct. 19 /PRNewswire/ -- Cellectis plant sciences, the plant genome engineering specialist and subsidiary of Cellectis (Alternext: ALCLS), announced today that it has signed a licensing agreement with Midwest Oilseeds Inc. for plant transformation technologies. The agreement provides Cellectis plant sciences with the ability to utilize Midwest's Aerosol Beam Injector (ABI) technology for precise modification of plant genomes.

Cellectis is a leader in meganuclease-based genome engineering. Its technology has many applications in plants, allowing for the insertion, deletion or modification of gene sequences to create plants expressing new traits with added value (for example: drought resistance, enhanced nutritional qualities, disease resistance). A subsidiary dedicated to the plant applications, Cellectis plant sciences, was established earlier this year in Saint Paul (Minnesota, USA), to enable the technology's full potential in plants and to deliver it to its partners.

The Aerosol Beam Injector (ABI) technology from Midwest Oilseeds allows functional meganucleases to be delivered directly into plant cells, thus avoiding the need for DNA vectors. This approach will allow Cellectis plant sciences to modify plant genomes without integration of foreign DNA.

"Coupling the ABI system with our highly specific meganucleases should allow for the creation of desired traits of interest," said Daniel Voytas, PhD, Chief Scientific Officer of Cellectis plant sciences. "The combination of technologies will enable the development of new crop varieties through more controlled modifications."

About Cellectis plant sciences

Established in March 2010, Cellectis plant sciences is a subsidiary of Cellectis dedicated to the applications of meganucleases to plants. Its main mission is to increase and accelerate usage of Cellectis' proprietary technology in agricultural biology, broaden the company's platform to attract new and expanded licensing opportunities and explore the development of proprietary traits for selected applications. Cellectis plant sciences is located in St. Paul, Minnesota, USA. Daniel Voytas, PhD, is serving as Chief Scientific Officer of Cellectis plant sciences. Dr Voytas is also Director of the University of Minnesota Center for Genome Engineering.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools - meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at

About Midwest Oilseeds Inc.

Midwest Oilseeds Inc. is focused on delivering the highest-yielding soybean germplasm in the seed industry. As the soybean genetics supplier of first choice to the seed industry, Midwest Oilseeds supplies a substantial portion of the soybean genetics planted in the United States today.


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
2. Cellectis Unveils Its New Corporate Website
3. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
4. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
5. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
6. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
7. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
8. Gem of an idea: A flexible diamond-studded electrode implanted for life
9. Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
10. Researchers expand yeasts sugary diet to include plant fiber
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 ... from 17 th until 19 th November 2015. ... invented the first combined scanner in the world which scans ... now two different scanners were required: one for passports and ... the same surface. This innovation is an ideal solution for ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):